Laura Cleary, MD
Dermatology · Chattanooga, TNNPI 1669891883
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,869 of the $13,136 with a category attached, or 82.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,813, 5.3 times the $723 reported in 2019.
Across 602 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Novartis$2K
- AbbVie$1K
- Lilly USA, LLC$1K
- Regeneron Healthcare Solutions, Inc.$855
- Sun Pharmaceutical Industries Inc.$777
- plus $5K from 29 others
What the payments were for
- Consulting fees$1,82014%
- Travel & lodging$3172%
- Food & beverage$10,86983%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 54 | $2,033 |
| Novartis | 83 | $1,819 |
| AbbVie | 85 | $1,433 |
| Lilly USA, LLC | 53 | $1,084 |
| Regeneron Healthcare Solutions, Inc. | 31 | $855 |
| Sun Pharmaceutical Industries Inc. | 42 | $777 |
| UCB, Inc. | 31 | $642 |
| Amgen | 29 | $596 |
| Sanofi | 20 | $576 |
| LEO Pharma Inc. | 22 | $446 |
| Dermavant Sciences, Inc. | 19 | $403 |
| Galderma Laboratories, L.p. | 25 | $369 |
| Pfizer | 16 | $353 |
| Revance Therapeutics, Inc. | 19 | $323 |
| Almirall LLC | 11 | $236 |
| E.r. Squibb & Sons, L.L.C. | 7 | $216 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $188 |
| Arcutis Biotherapeutics, Inc. | 7 | $117 |
| Helsinn Therapeutics (U.S.), Inc. | 6 | $91 |
| Chiesi USA, Inc. | 3 | $89 |
| Incyte Corporation | 4 | $84 |
| Boehringer Ingelheim | 3 | $62 |
| Bristol Myers Squibb | 4 | $56 |
| DUSA Pharmaceuticals, Inc. | 3 | $48 |
| Genentech USA, Inc. | 2 | $36 |
| Organon | 2 | $31 |
| Mayne Pharma Commercial LLC | 2 | $25 |
| Kerecis Limited | 1 | $25 |
| EPI Health, LLC | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $21 |
| Medtronic | 1 | $18 |
| Prugen, Inc. Pharmaceuticals | 1 | $18 |
| Acera Surgical, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,136 in reported general payments places this provider in the 80th percentile of 209 dermatology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 47 | $179,974 |
| Taltz AutoinjectorIxekizumab | 16 | $112,588 |
| OtezlaApremilast | 13 | $52,415 |
| Clobetasol Propionate | 210 | $11,104 |
| Ketoconazole | 278 | $3,867 |
| Tacrolimus | 32 | $3,849 |
| Fluorouracil | 35 | $2,791 |
| Metronidazole | 23 | $1,660 |
| Triamcinolone Acetonide | 113 | $916 |
| Doxycycline Hyclate | 50 | $909 |
| Spironolactone | 41 | $897 |
| Hydrocortisone | 92 | $680 |
| Clindamycin Phosphate | 32 | $577 |
| Finasteride | 66 | $460 |
| ValacyclovirValacyclovir Hcl | 34 | $418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $596 | $52,41513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 209 dermatology providers in Tennessee.
Other dermatology in Chattanooga
- Cara HenningsChattanooga$15K
- Samuel BanksChattanooga$11K
- Kimberly VincentNashville$1.5M
- Adrian RodriguezNashville$1.1M
- Michael GoldNashville$748K
- Joni SagoKingsport$661K
- Jennifer LeeBrentwood$396K
- Christina FeserClarksville$383K
- Emily OverholserMemphis$322K
- James TurnerBartlett$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.